{"id":389317,"date":"2022-12-26T00:00:00","date_gmt":"2022-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0009-2022-biopharma-breast-cancer-china-in-depth-china-2022\/"},"modified":"2026-03-31T10:35:33","modified_gmt":"2026-03-31T10:35:33","slug":"concon0009-2022-biopharma-breast-cancer-china-in-depth-china-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0009-2022-biopharma-breast-cancer-china-in-depth-china-2022\/","title":{"rendered":"Breast Cancer | China In-Depth | China | 2022"},"content":{"rendered":"<p>Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies\u2014including pertuzumab (Roche\u2019s Perjeta) and ado-trastuzumab emtansine (Roche\u2019s Kadcyla)\u2014have launched there in the last few years. The inclusion of these therapies in the National Reimbursement Drug List (NRDL) has improved the drug-treatment rate for breast cancer in China and resulted in significant market growth. We expect many more premium-priced breast cancer therapies\u2014currently in the late-phase pipeline\u2014to launch in China during the forecast period, further expanding this market. However, unmet need will remain in the treatment of difficult-to-treat breast cancer populations (e.g., triple-negative disease), presenting continued commercial opportunity for developers in this space. Additionally, in view of the ongoing reforms of China\u2019s regulatory and access and reimbursement landscape, developers\u2014both domestic and multinational\u2014will be increasingly encouraged to enter this market.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul>\n<li>How large is China\u2019s drug-treatable breast cancer population, and how will drug-treatment rates change during the forecast period?<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s breast cancer therapy market, and why? What are interviewed experts\u2019 insights into current treatments?<\/li>\n<li>What are the market access considerations for key therapies in the breast cancer pipeline in China? What sales could these agents secure in breast cancer? What are interviewed experts\u2019 opinions of key emerging therapies?<\/li>\n<li>What are the key drivers and constraints in China\u2019s breast cancer therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>China In-Depth<\/em> offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&#038;R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n<p><strong>Release date<\/strong><\/p>\n<p>June 2022<\/p>\n<p><strong>Geography<\/strong><\/p>\n<p>China<\/p>\n<p><strong>Primary research <\/strong><\/p>\n<p>Country-specific qualitative and quantitative insights based on 5 thought-leader interviews and surveys of 75 medical oncologists.<\/p>\n<p><strong>Epidemiology <\/strong><\/p>\n<p>Diagnosed incidence of breast cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p><strong>E<\/strong><strong>MERGING<\/strong><strong> THERAPIES<\/strong><\/p>\n<p>Phase III\/preregistered: 20+ drugs; Phase II: 20+ drugs; coverage of select Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-389317","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389317\/revisions"}],"predecessor-version":[{"id":576149,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389317\/revisions\/576149"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}